Erratum: Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma (Journal of Neuro-Oncology DOI: 10.1007/s11060-011-0555-z);Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma

Journal of Neuro-Oncology

Volumn 104, Issue 3, 2011, Pages 825-831

  Song, Moo Kon ^a   Chung, Joo Seop ^a   Joo, Young Don ^b   Lee, Sang Min ^b   Oh, Sung Yong ^c   Shin, Dong Hoon ^a   Yun, Eun Young ^d   Kim, Seung Geun ^a   Seol, Young Mi ^a   Shin, Ho Jin ^a   Choi, Young Jin ^a   Cho, Goon Jae ^a  

^a Pusan National University Hospital   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Dong A University   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

Bcl 6; ECOG; Primary CNS lymphoma

Indexed keywords

KI 67 ANTIGEN; LACTATE DEHYDROGENASE; METHOTREXATE; PROTEIN BCL 6;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 80052616325     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0566-9     Document Type: Erratum

References (20)

1. FH Hochberg JM Baehring EP Hochberg 2007 Primary CNS lymphoma Nat Clin Pract Neurol 3 1 24 35 17205072 10.1038/ncpneuro0395 1:CAS:528: DC%2BD2sXhsVSkt7g%3D (Pubitemid 46056031)
2. TR Coté A Manns CR Hardy FJ Yellin P Hartge 1996 Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group J Natl Cancer Inst 88 10 675 679 8627644 10.1093/jnci/88.10.675 (Pubitemid 26152554)
3. J Corry JG Smith A Wirth G Quong KH Liew 1998 Primary central nervous system lymphoma: age and performance status are more important than treatment modality Int J Radiat Oncol Biol Phys 41 3 615 620 9635710 10.1016/S0360- 3016(97)00571-3 1:STN:280:DyaK1c3pslKgsQ%3D%3D (Pubitemid 28275092)
4. LE Abrey J Yahalom LM DeAngelis 2000 Treatment for primary CNS lymphoma: the next step J Clin Oncol 18 17 3144 3150 10963643 1:CAS:528: DC%2BD3cXntVCgsbs%3D
5. M Reni AJ Ferreri MP Garancini E Villa 1997 Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature Ann Oncol 8 3 227 234 9137790 10.1023/A:1008201717089 1:STN:280:DyaK2s3otlOisA%3D%3D (Pubitemid 27153487)
6. AJ Ferreri JY Blay M Reni F Pasini M Spina A Ambrosetti, et al. 2003 Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience J Clin Oncol 21 2 266 272 12525518 10.1200/JCO.2003.09.139 (Pubitemid 46606155)
7. Gabbai AA, Hochberg FH, Linggood RM, Bashir R, Hotleman K. Gabbai AA et al. (1989) Hochberg FH, Linggood RM, Bashir R, Hotleman K. High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases. J Neurosurg 70(2):190-194 (Pubitemid 19051713)
8. LM DeAngelis J Yahalom HT Thaler U Kher 1992 Combined modality therapy for primary CNS lymphoma J Clin Oncol 10 4 635 643 1548527 1:STN:280: DyaK387ptl2ktw%3D%3D
9. LM DeAngelis W Seiferheld SC Schold B Fisher CJ Schultz 2002 Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10 J Clin Oncol 20 24 4643 4648 12488408 10.1200/JCO.2002.11.013 (Pubitemid 36025280)
10. PM Poortmans HC Kluin-Nelemans H Haaxma-Reiche M Van't Veer M Hansen P Soubeyran, et al. 2003 European Organization for Research and Treatment of Cancer Lymphoma Group. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962 J Clin Oncol 21 24 4483 4488 14597741 10.1200/JCO.2003.03.108 1:CAS:528:DC%2BD2cXpsVWqtbg%3D (Pubitemid 46594017)
11. CH Lin KT Kuo SS Chuang SH Kuo JH Chang KC Chang, et al. 2006 Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin Clin Cancer Res 12 4 1152 1156 16489068 10.1158/1078-0432.CCR-05- 1699 1:CAS:528:DC%2BD28XhsFalt7k%3D (Pubitemid 43342503)
12. O Levy LM Deangelis DA Filippa KS Panageas LE Abrey 2008 Bcl-6 predicts improved prognosis in primary central nervous system lymphoma Cancer 112 1 151 156 17999414 10.1002/cncr.23149
13. KM Braaten RA Betensky L de Leval Y Okada FH Hochberg DN Louis, et al. 2003 BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma Clin Cancer Res 9 3 1063 1069 12631608 1:CAS:528:DC%2BD3sXhvFKitL0%3D (Pubitemid 36329149)
14. EM Bessell F Graus A Lopez-Guillermo SA Lewis S Villa E Verger, et al. 2004 Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors Int J Radiat Oncol Biol Phys 59 2 501 508 15145169 10.1016/j.ijrobp.2003.11.001 (Pubitemid 38622607)
15. LE Abrey L Ben-Porat KS Panageas J Yahalom B Berkey W Curran, et al. 2006 Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model J Clin Oncol 24 36 5711 5715 17116938 10.1200/JCO.2006.08.2941 (Pubitemid 46631313)
16. Y Sugita O Tokunaga A Nakashima M Shigemori 2004 SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts Pathol Int 54 9 659 666 15363033 10.1111/j.1440-1827.2004.01677.x 1:CAS:528:DC%2BD2cXpt1ajurw%3D (Pubitemid 39297290)
17. S Camilleri-Broët E Crinière P Broët V Delwail K Mokhtari A Moreau, et al. 2005 A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases Blood 107 1 190 196 16150948 10.1182/blood-2005-03-1024 (Pubitemid 43053543)
18. M Krogh-Jensen P Johansen F D'Amore 1998 Primary central nervous system lymphomas in immunocompetent individuals: histology, Epstein-Barr virus genome, Ki-67 proliferation index, p53 and bcl-2 gene expression Leuk Lymphoma 30 12 131 142 9669683 1:CAS:528:DC%2BD3cXisFOhtL4%3D (Pubitemid 28327262)
19. JY Blay T Conroy C Chevreau A Thyss N Quesnel H Eghbali, et al. 1998 High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series J Clin Oncol 16 3 864 871 9508167 1:CAS:528:DyaK1cXitVKis70%3D (Pubitemid 28108718)
20. JY Blay C Lasset C Carrie F Chauvin B Coiffier C Gisselbrecht, et al. 1993 Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring Br J Cancer 67 5 1136 1141 8494713 10.1038/bjc.1993.209 1:STN:280: DyaK3s3msVWqtA%3D%3D (Pubitemid 23147518)